

# Global Targeted PSMA Radionuclide Drug Conjugates Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/GE65A8C4AA76EN.html>

Date: May 2026

Pages: 107

Price: US\$ 4,480.00 (Single User License)

ID: GE65A8C4AA76EN

## Abstracts

The global Targeted PSMA Radionuclide Drug Conjugates market size is expected to reach \$ 3466 million by 2032, rising at a market growth of 7.5% CAGR during the forecast period (2026-2032).

Targeted PSMA Radionuclide Drug Conjugates are precision radiotherapeutics designed to selectively deliver therapeutic radioisotopes to tumor tissue by targeting prostate-specific membrane antigen, or PSMA. These products are typically composed of a PSMA-targeting small molecule or ligand, a chelator, and a therapeutic radionuclide. Among current commercialized and clinical-stage products, <sup>177</sup>Lu-labeled agents are the most mature, while alpha-emitting candidates such as <sup>225</sup>Ac-based products are still largely in clinical development or early-stage application. This category is primarily used for the treatment of PSMA-positive advanced prostate cancer, especially metastatic castration-resistant prostate cancer, or mCRPC. Upstream segments mainly include targeting ligands and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of hospitals with nuclear medicine capabilities, cancer centers, specialty treatment networks, and radiopharmaceutical distribution systems. On a commercial-market basis, the global market in 2025 remained centered on Novartis' Pluvicto, and the industry as a whole continued to show the characteristics of limited marketed products, an active clinical pipeline, and simultaneous technical and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized targeted PSMA radionuclide drug conjugates is estimated to

be in the range of 55%-70%.

At present, the targeted PSMA radionuclide drug conjugate industry is in a stage driven by a limited number of commercialized products while accelerating into broader treatment settings. As the leading marketed products gradually move toward earlier lines of therapy, the sector is shifting from late-line clinical validation to a phase characterized by indication expansion and platform-based commercialization. This indicates that both the clinical value and commercial feasibility of the category are continuing to strengthen. Overall, market attention, capital investment, and pipeline activity are all increasing, and the industry is evolving from isolated product breakthroughs toward sustained competition centered on platform capability and indication expansion.

From the perspective of technology and product evolution, the  $^{177}\text{Lu}$  route is expected to remain the mainstream direction in the medium term because of its relatively mature clinical pathway, more established industrial infrastructure, and stronger commercialization foundation. At the same time, however, the industry is moving from competition around individual products to competition around platform capability. Future development is likely to focus not only on new ligand structures, combination regimens, and earlier treatment settings, but also on accelerated deployment of alpha-emitter approaches such as  $^{225}\text{Ac}$  in pursuit of stronger biological effects and differentiated therapeutic value. As leading companies continue to broaden their radioligand therapy portfolios, targeted PSMA drugs are likely to evolve from a single advanced prostate cancer therapy into a core component of broader radiopharmaceutical oncology platforms.

From an industrialization perspective, supply chain and manufacturing systems will be the key variables determining how quickly the industry can scale. Compared with conventional oncology drugs, targeted PSMA radionuclide drug conjugates place much higher demands on isotope supply, specialized manufacturing facilities, quality release, time-sensitive distribution, and hospital nuclear medicine capabilities. In the future, leading companies are expected to continue strengthening delivery resilience by expanding radiopharmaceutical production sites, building regional manufacturing networks, and increasing treatment-center coverage. As a result, competition will no longer be limited to the drug itself, but will increasingly become competition in integrated capabilities spanning product, manufacturing, logistics, and hospital access. In other words, companies that establish stable isotope access and strong treatment networks earlier will be better positioned in the commercialization phase.

Nevertheless, the industry still faces several constraints. Stable isotope supply, the construction cycle of dedicated capacity, and the availability of specialized treatment centers remain practical bottlenecks to market expansion. In addition, patient treatment pathways usually rely on PSMA imaging selection and supporting nuclear medicine infrastructure, while reimbursement systems, hospital access, and treatment standards differ significantly across countries and regions, making global market expansion uneven. As the category moves into earlier treatment settings and addresses a broader patient population, requirements for safety management, treatment standardization, and long-term follow-up data will also continue to rise. Overall, targeted PSMA radionuclide drug conjugates offer clear long-term growth potential, but future expansion is more likely to be gradual and system-driven, supported jointly by clinical evidence, supply assurance, and healthcare infrastructure development, rather than by rapid short-term scaling.

This report studies the global Targeted PSMA Radionuclide Drug Conjugates demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Targeted PSMA Radionuclide Drug Conjugates, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Targeted PSMA Radionuclide Drug Conjugates that contribute to its increasing demand across many markets.

### **Highlights and key features of the study**

Global Targeted PSMA Radionuclide Drug Conjugates total market, 2021-2032, (USD Million)

Global Targeted PSMA Radionuclide Drug Conjugates total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Targeted PSMA Radionuclide Drug Conjugates total market, key domestic companies, and share, (USD Million)

Global Targeted PSMA Radionuclide Drug Conjugates revenue by player, revenue and market share 2021-2026, (USD Million)

Global Targeted PSMA Radionuclide Drug Conjugates total market by Type, CAGR, 2021-2032, (USD Million)

Global Targeted PSMA Radionuclide Drug Conjugates total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Targeted PSMA Radionuclide Drug

Conjugates market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Curium, Telix Pharmaceuticals, Lantheus, Fusion Pharmaceuticals, Blue Earth Therapeutics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Targeted PSMA Radionuclide Drug Conjugates market

### **Detailed Segmentation:**

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Targeted PSMA Radionuclide Drug Conjugates Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Targeted PSMA Radionuclide Drug Conjugates Market, Segmentation by Type:

Monotherapy Products

Combination Therapy Products

Global Targeted PSMA Radionuclide Drug Conjugates Market, Segmentation by Radionuclide Type:

Beta-emitting

Alpha-emitting

Other

Global Targeted PSMA Radionuclide Drug Conjugates Market, Segmentation by Targeting Vector Type:

Small-molecule

Antibody-based

Other

Global Targeted PSMA Radionuclide Drug Conjugates Market, Segmentation by Application:

Hospital

Clinic

Others

Companies Profiled:

Novartis

Curium

Telix Pharmaceuticals

Lantheus

Fusion Pharmaceuticals

Blue Earth Therapeutics

### Key Questions Answered

1. How big is the global Targeted PSMA Radionuclide Drug Conjugates market?
2. What is the demand of the global Targeted PSMA Radionuclide Drug Conjugates market?
3. What is the year over year growth of the global Targeted PSMA Radionuclide Drug Conjugates market?
4. What is the total value of the global Targeted PSMA Radionuclide Drug Conjugates market?
5. Who are the Major Players in the global Targeted PSMA Radionuclide Drug Conjugates market?
6. What are the growth factors driving the market demand?

## Contents

### 1 SUPPLY SUMMARY

- 1.1 Targeted PSMA Radionuclide Drug Conjugates Introduction
- 1.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World Targeted PSMA Radionuclide Drug Conjugates Total Market by Region (by Headquarter Location)
  - 1.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (2021-2032), (by Headquarter Location)
  - 1.3.2 United States Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
  - 1.3.3 China Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
  - 1.3.4 Europe Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
  - 1.3.5 Japan Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
  - 1.3.6 South Korea Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
  - 1.3.7 ASEAN Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
  - 1.3.8 India Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
  - 1.4.1 Targeted PSMA Radionuclide Drug Conjugates Market Drivers
  - 1.4.2 Factors Affecting Demand
  - 1.4.3 Major Market Trends

### 2 DEMAND SUMMARY

- 2.1 World Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
- 2.2 World Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region
  - 2.2.1 World Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2021-2026)
  - 2.2.2 World Targeted PSMA Radionuclide Drug Conjugates Consumption Value

Forecast by Region (2027-2032)

2.3 United States Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)

2.4 China Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)

2.5 Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)

2.6 Japan Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)

2.7 South Korea Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)

2.8 ASEAN Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)

2.9 India Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)

### **3 WORLD TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES COMPANIES COMPETITIVE ANALYSIS**

3.1 World Targeted PSMA Radionuclide Drug Conjugates Revenue by Player (2021-2026)

3.2 Industry Rank and Concentration Rate (CR)

3.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Industry Rank of Major Players

3.2.2 Global Concentration Ratios (CR4) for Targeted PSMA Radionuclide Drug Conjugates in 2025

3.2.3 Global Concentration Ratios (CR8) for Targeted PSMA Radionuclide Drug Conjugates in 2025

3.3 Targeted PSMA Radionuclide Drug Conjugates Company Evaluation Quadrant

3.4 Targeted PSMA Radionuclide Drug Conjugates Market: Overall Company Footprint Analysis

3.4.1 Targeted PSMA Radionuclide Drug Conjugates Market: Region Footprint

3.4.2 Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Type Footprint

3.4.3 Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Application Footprint

3.5 Competitive Environment

3.5.1 Historical Structure of the Industry

3.5.2 Barriers of Market Entry

- 3.5.3 Factors of Competition
- 3.6 Mergers & Acquisitions Activity

## **4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)**

### 4.1 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Revenue Comparison (by Headquarter Location)

4.1.1 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)

4.1.2 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share Comparison (2021 & 2025 & 2032)

### 4.2 United States Based Companies VS China Based Companies: Targeted PSMA Radionuclide Drug Conjugates Consumption Value Comparison

4.2.1 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Consumption Value Comparison (2021 & 2025 & 2032)

4.2.2 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share Comparison (2021 & 2025 & 2032)

### 4.3 United States Based Targeted PSMA Radionuclide Drug Conjugates Companies and Market Share, 2021-2026

4.3.1 United States Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue, (2021-2026)

### 4.4 China Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue and Market Share, 2021-2026

4.4.1 China Based Targeted PSMA Radionuclide Drug Conjugates Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue, (2021-2026)

### 4.5 Rest of World Based Targeted PSMA Radionuclide Drug Conjugates Companies and Market Share, 2021-2026

4.5.1 Rest of World Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (Province, Country)

4.5.2 Rest of World Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2026)

## **5 MARKET ANALYSIS BY TYPE**

5.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Type: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 Monotherapy Products

5.2.2 Combination Therapy Products

5.3 Market Segment by Type

5.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026)

5.3.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2027-2032)

5.3.3 World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2027-2032)

## **6 MARKET ANALYSIS BY RADIONUCLIDE TYPE**

6.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Radionuclide Type: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Radionuclide Type

6.2.1 Beta-emitting

6.2.2 Alpha-emitting

6.2.3 Other

6.3 Market Segment by Radionuclide Type

6.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type (2021-2026)

6.3.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type (2027-2032)

6.3.3 World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2027-2032)

## **7 MARKET ANALYSIS BY TARGETING VECTOR TYPE**

7.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Targeting Vector Type: 2021 VS 2025 VS 2032

7.2 Segment Introduction by Targeting Vector Type

7.2.1 Small-molecule

7.2.2 Antibody-based

7.2.3 Other

7.3 Market Segment by Targeting Vector Type

7.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting

Vector Type (2021-2026)

7.3.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type (2027-2032)

7.3.3 World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2027-2032)

## **8 MARKET ANALYSIS BY APPLICATION**

8.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Application: 2021 VS 2025 VS 2032

8.2 Segment Introduction by Application

8.2.1 Hospital

8.2.2 Clinic

8.2.3 Others

8.3 Market Segment by Application

8.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026)

8.3.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2027-2032)

8.3.3 World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2032)

## **9 COMPANY PROFILES**

9.1 Novartis

9.1.1 Novartis Details

9.1.2 Novartis Major Business

9.1.3 Novartis Targeted PSMA Radionuclide Drug Conjugates Product and Services

9.1.4 Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)

9.1.5 Novartis Recent Developments/Updates

9.1.6 Novartis Competitive Strengths & Weaknesses

9.2 Curium

9.2.1 Curium Details

9.2.2 Curium Major Business

9.2.3 Curium Targeted PSMA Radionuclide Drug Conjugates Product and Services

9.2.4 Curium Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)

9.2.5 Curium Recent Developments/Updates

### 9.2.6 Curium Competitive Strengths & Weaknesses

## 9.3 Telix Pharmaceuticals

### 9.3.1 Telix Pharmaceuticals Details

### 9.3.2 Telix Pharmaceuticals Major Business

### 9.3.3 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Services

### 9.3.4 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)

### 9.3.5 Telix Pharmaceuticals Recent Developments/Updates

### 9.3.6 Telix Pharmaceuticals Competitive Strengths & Weaknesses

## 9.4 Lantheus

### 9.4.1 Lantheus Details

### 9.4.2 Lantheus Major Business

### 9.4.3 Lantheus Targeted PSMA Radionuclide Drug Conjugates Product and Services

### 9.4.4 Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)

### 9.4.5 Lantheus Recent Developments/Updates

### 9.4.6 Lantheus Competitive Strengths & Weaknesses

## 9.5 Fusion Pharmaceuticals

### 9.5.1 Fusion Pharmaceuticals Details

### 9.5.2 Fusion Pharmaceuticals Major Business

### 9.5.3 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Services

### 9.5.4 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)

### 9.5.5 Fusion Pharmaceuticals Recent Developments/Updates

### 9.5.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses

## 9.6 Blue Earth Therapeutics

### 9.6.1 Blue Earth Therapeutics Details

### 9.6.2 Blue Earth Therapeutics Major Business

### 9.6.3 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product and Services

### 9.6.4 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)

### 9.6.5 Blue Earth Therapeutics Recent Developments/Updates

### 9.6.6 Blue Earth Therapeutics Competitive Strengths & Weaknesses

## 10 INDUSTRY CHAIN ANALYSIS

- 10.1 Targeted PSMA Radionuclide Drug Conjugates Industry Chain
- 10.2 Targeted PSMA Radionuclide Drug Conjugates Upstream Analysis
- 10.3 Targeted PSMA Radionuclide Drug Conjugates Midstream Analysis
- 10.4 Targeted PSMA Radionuclide Drug Conjugates Downstream Analysis

## **11 RESEARCH FINDINGS AND CONCLUSION**

## **12 APPENDIX**

- 12.1 Methodology
- 12.2 Research Process and Data Source
- 12.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Table 2. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)

Table 3. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)

Table 4. World Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Region (2021-2026), (by Headquarter Location)

Table 5. World Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Region (2027-2032), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)

Table 8. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2021-2026) & (USD Million)

Table 9. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value Forecast by Region (2027-2032) & (USD Million)

Table 10. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Player (2021-2026) & (USD Million)

Table 11. Revenue Market Share of Key Targeted PSMA Radionuclide Drug Conjugates Players in 2025

Table 12. World Targeted PSMA Radionuclide Drug Conjugates Industry Rank of Major Player, Based on Revenue in 2025

Table 13. Global Targeted PSMA Radionuclide Drug Conjugates Company Evaluation Quadrant

Table 14. Head Office of Key Targeted PSMA Radionuclide Drug Conjugates Players

Table 15. Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Type Footprint

Table 16. Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Application Footprint

Table 17. Targeted PSMA Radionuclide Drug Conjugates Mergers & Acquisitions Activity

Table 18. United States VS China Targeted PSMA Radionuclide Drug Conjugates Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 19. United States VS China Targeted PSMA Radionuclide Drug Conjugates

Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 20. United States Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (States, Country)

Table 21. United States Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue, (2021-2026) & (USD Million)

Table 22. United States Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share (2021-2026)

Table 23. China Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (Province, Country)

Table 24. China Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue, (2021-2026) & (USD Million)

Table 25. China Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share (2021-2026)

Table 26. Rest of World Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (Province, Country)

Table 27. Rest of World Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2026) & (USD Million)

Table 28. Rest of World Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share (2021-2026)

Table 29. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type, (USD Million), 2021 & 2025 & 2032

Table 30. World Targeted PSMA Radionuclide Drug Conjugates Market Size Value by Type (2021-2026) & (USD Million)

Table 31. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2027-2032) & (USD Million)

Table 32. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type, (USD Million), 2021 & 2025 & 2032

Table 33. World Targeted PSMA Radionuclide Drug Conjugates Market Size Value by Radionuclide Type (2021-2026) & (USD Million)

Table 34. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type (2027-2032) & (USD Million)

Table 35. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type, (USD Million), 2021 & 2025 & 2032

Table 36. World Targeted PSMA Radionuclide Drug Conjugates Market Size Value by Targeting Vector Type (2021-2026) & (USD Million)

Table 37. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type (2027-2032) & (USD Million)

Table 38. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application, (USD Million), 2021 & 2025 & 2032

Table 39. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026) & (USD Million)

Table 40. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2027-2032) & (USD Million)

Table 41. Novartis Basic Information, Manufacturing Base and Competitors

Table 42. Novartis Major Business

Table 43. Novartis Targeted PSMA Radionuclide Drug Conjugates Product and Services

Table 44. Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 45. Novartis Recent Developments/Updates

Table 46. Novartis Competitive Strengths & Weaknesses

Table 47. Curium Basic Information, Manufacturing Base and Competitors

Table 48. Curium Major Business

Table 49. Curium Targeted PSMA Radionuclide Drug Conjugates Product and Services

Table 50. Curium Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 51. Curium Recent Developments/Updates

Table 52. Curium Competitive Strengths & Weaknesses

Table 53. Telix Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 54. Telix Pharmaceuticals Major Business

Table 55. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Services

Table 56. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 57. Telix Pharmaceuticals Recent Developments/Updates

Table 58. Telix Pharmaceuticals Competitive Strengths & Weaknesses

Table 59. Lantheus Basic Information, Manufacturing Base and Competitors

Table 60. Lantheus Major Business

Table 61. Lantheus Targeted PSMA Radionuclide Drug Conjugates Product and Services

Table 62. Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 63. Lantheus Recent Developments/Updates

Table 64. Lantheus Competitive Strengths & Weaknesses

Table 65. Fusion Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 66. Fusion Pharmaceuticals Major Business

Table 67. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Services

Table 68. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 69. Fusion Pharmaceuticals Recent Developments/Updates

Table 70. Fusion Pharmaceuticals Competitive Strengths & Weaknesses

Table 71. Blue Earth Therapeutics Basic Information, Manufacturing Base and Competitors

Table 72. Blue Earth Therapeutics Major Business

Table 73. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product and Services

Table 74. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 75. Blue Earth Therapeutics Recent Developments/Updates

Table 76. Blue Earth Therapeutics Competitive Strengths & Weaknesses

Table 77. Global Key Players of Targeted PSMA Radionuclide Drug Conjugates Upstream (Raw Materials)

Table 78. Global Targeted PSMA Radionuclide Drug Conjugates Typical Customers

## List Of Figures

### LIST OF FIGURES

- Figure 1. Targeted PSMA Radionuclide Drug Conjugates Picture
- Figure 2. World Targeted PSMA Radionuclide Drug Conjugates Total Revenue: 2021 & 2025 & 2032, (USD Million)
- Figure 3. World Targeted PSMA Radionuclide Drug Conjugates Total Revenue (2021-2032) & (USD Million)
- Figure 4. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
- Figure 5. World Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Region (2021-2032), (by Headquarter Location)
- Figure 6. United States Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
- Figure 7. China Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
- Figure 8. Europe Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
- Figure 9. Japan Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
- Figure 10. South Korea Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
- Figure 11. ASEAN Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
- Figure 12. India Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
- Figure 13. Targeted PSMA Radionuclide Drug Conjugates Market Drivers
- Figure 14. Factors Affecting Demand
- Figure 15. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
- Figure 16. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Region (2021-2032)
- Figure 17. United States Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
- Figure 18. China Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
- Figure 19. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)

Figure 20. Japan Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)

Figure 21. South Korea Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)

Figure 23. India Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of Targeted PSMA Radionuclide Drug Conjugates by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for Targeted PSMA Radionuclide Drug Conjugates Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for Targeted PSMA Radionuclide Drug Conjugates Markets in 2025

Figure 27. United States VS China: Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type, (USD Million), 2021 & 2025 & 2032

Figure 30. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type in 2025

Figure 31. Monotherapy Products

Figure 32. Combination Therapy Products

Figure 33. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2032)

Figure 34. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type, (USD Million), 2021 & 2025 & 2032

Figure 35. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type in 2025

Figure 36. Beta-emitting

Figure 37. Alpha-emitting

Figure 38. Other

Figure 39. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2021-2032)

Figure 40. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type, (USD Million), 2021 & 2025 & 2032

Figure 41. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type in 2025

Figure 42. Small-molecule

Figure 43. Antibody-based

Figure 44. Other

Figure 45. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2021-2032)

Figure 46. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 47. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application in 2025

Figure 48. Hospital

Figure 49. Clinic

Figure 50. Others

Figure 51. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2032)

Figure 52. Targeted PSMA Radionuclide Drug Conjugates Industrial Chain

Figure 53. Methodology

Figure 54. Research Process and Data Source

## I would like to order

Product name: Global Targeted PSMA Radionuclide Drug Conjugates Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/GE65A8C4AA76EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE65A8C4AA76EN.html>